# Stevanato Group S.p.A. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/Stevanato Group S.p.A.). ## Overview Stevanato Group S.p.A. is an Italy-based healthcare packaging and device company that supplies drug containment, delivery, and diagnostic solutions to pharmaceutical, biotechnology, and life sciences customers. Its business combines specialty glass and plastic packaging, drug delivery systems, in-vitro diagnostic products, and engineering services across the drug development and commercial supply chain. ## Products & services • Drug containment solutions for injectable medicines • Drug delivery systems for patient administration • In-vitro diagnostic solutions and components • Engineering and custom construction services • Integrated packaging and lifecycle support - **Drug Containment Solutions** (40%) — Primary packaging such as vials, cartridges, syringes, and related containment products for injectable drugs. - **Biopharmaceutical and Diagnostic Solutions** (35%) — Drug delivery, diagnostic, and other healthcare solutions sold to pharma and diagnostics customers. - **Engineering** (15%) — Custom machinery, line integration, and customer-specific construction projects for pharmaceutical production. - **In-Vitro Diagnostic Solutions** (10%) — Diagnostic components and related products used in laboratory and testing workflows. - Drug containment solutions for injectable medicines - Drug delivery systems for patient administration - In-vitro diagnostic solutions and components - Engineering and custom construction services - Integrated packaging and lifecycle support ## Customers Stevanato sells to pharmaceutical, biotechnology, and life sciences companies that need high-integrity primary packaging and delivery systems. It also serves diagnostics customers and drug manufacturers that require custom engineering, technical collaboration, and validated supply capability across development and commercial production. End markets highlighted in the reports include biologics, vaccines, insulin, small molecules and generics, and molecular diagnostics. - **Pharmaceutical manufacturers** (primary) — Buy vials, syringes, cartridges, and delivery systems for commercial drug supply. - **Biotechnology and biologics companies** (primary) — Buy containment and delivery solutions for biologics, including high-value injectable therapies. - **Diagnostics companies** (secondary) — Buy in-vitro diagnostic products and components used in testing workflows. - **Contract manufacturing and drug developers** (secondary) — Buy engineering services and integrated solutions for development and scale-up. - **End-market drug categories** (secondary) — Exposure to vaccines, insulin, small molecules, generics, and molecular diagnostics demand. - Pharma companies buying sterile primary packaging for injectables - Biotech customers needing containment for biologics and GLP products - Diagnostics customers sourcing assay and testing components - Drug manufacturers needing delivery systems and device components - Engineering customers requiring custom production line solutions ## Geography The group is headquartered in Piombino Dese, near Padua, Italy, and operates as an Italian multinational with a global customer base. Its manufacturing and commercialization footprint serves pharmaceutical and diagnostics customers across major healthcare markets, with business exposure tied to where injectable drugs and diagnostic products are developed and produced. The reports do not provide an authoritative revenue-by-country split in the supplied excerpts. - Headquartered in Piombino Dese (Padua), Italy - Operates as an Italian multinational healthcare supplier - Serves global pharma and diagnostics customers - Exposure follows injectable-drug and diagnostics manufacturing hubs - No country revenue split disclosed in supplied excerpts ## Strategy Stevanato Group focuses on integrated solutions that preserve drug integrity, reduce time to market, and lower total cost of ownership for customers. Its strategy is built around co-developing products with customers, leveraging scientific and engineering capabilities, and participating across both direct markets such as drug containment and end markets such as biologics and diagnostics. - **Integrated end-to-end healthcare solutions** (medium-term) — Customers value suppliers that can support packaging, delivery, diagnostics, and engineering together. - **Customer collaboration and product development** (medium-term) — Co-development helps secure long-term programs and tighter technical integration with pharma customers. - **Expansion in biologics and other end markets** (long-term) — These end markets drive demand for advanced containment and delivery solutions. - Co-develop solutions with pharma and biotech customers - Expand integrated offerings across the drug lifecycle - Use engineering capability to deepen customer relationships - Participate in high-value end markets such as biologics - Serve multiple product families to broaden customer reach ## Risks The business depends on pharmaceutical development cycles, customer qualification, and the adoption of specific drug formats, which can delay projects or shift demand across product categories. It also faces manufacturing, quality, and supply-chain execution risk because its products are tightly integrated into regulated healthcare supply chains. Accounting estimates around variable consideration, contract assets/liabilities, and impairment testing can materially affect reported results when projects change or customer volumes move. - **Customer program timing and qualification delays** [high] — Customers buy validated packaging and delivery systems tied to drug development and launch milestones. - **Manufacturing quality and regulatory compliance** [high] — Products are used in sterile and regulated healthcare applications, where defects can disrupt customer supply. - **Project execution on customer-specific construction contracts** [medium] — Engineering revenues depend on delivery, scope control, and milestone achievement on custom contracts. - **Demand mix shifts in biologics, vaccines, and GLP-related products** [medium] — The company’s end markets can change as drug pipelines, launches, and therapeutic preferences evolve. - Customer concentration and program timing can shift demand - Regulated manufacturing and quality failures could disrupt supply - Engineering contracts carry project execution and margin risk - End-market shifts in biologics, GLP products, or diagnostics affect mix - Estimates for revenue, contract balances, and impairment require judgment ## Accounting Revenue recognition depends on whether sales are recognized over time for customer-specific engineering contracts or at a point in time for product sales, so the timing of shipments and project milestones can move revenue between periods. The company also uses estimates for variable consideration, contract assets and liabilities, and impairment testing, which means reported results can change with updated customer information, project progress, or asset reviews. - **Revenue recognition timing** — Affects quarterly revenue and working capital balances - **Variable consideration** — Can change reported sales and margins - **Contract assets and liabilities** — Affects balance sheet and cash conversion - **Impairment testing** — Could create non-cash charges if assumptions weaken - Point-in-time vs over-time revenue affects timing of recognition - Variable consideration estimates can change reported revenue - Contract assets and liabilities reflect engineering and custom projects - Impairment testing matters for goodwill and long-lived assets - Employee benefit and tax estimates can move interim results --- *Last updated: 2026-09-28T12:14:09.021762+00:00*